Fresenius SE & Co.’s minority-owned kidney dialysis business agreed Monday to acquire NxStage Medical Inc. for about $2 billion as part of the German health-care provider’s broader push into the U.S. The NxStage deal comes less than five months after Fresenius SE, which owns 31% of Fresenius Medical Care, agreed to acquire U.S. generics drug manufacturer Akorn Inc. for $4.3 billion. That deal aimed to bolster and diversify its...

Source: Wall Street Journal August 07, 2017 11:26 UTC